Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 9 posts of 9594 posts found.

Waiting for the upturn

October 15, 2003 Research and Development drug development, pipelines

Estimates vary considerably, but many analysts put the current cost of bringing a drug to market at around $800 million, …
Feature

Project management – you get what you pay for

October 15, 2003 Research and Development project management

Pharma projects have project managers. Technology projects have project managers. But there is a world of difference between them. That …
Feature

Powering up the pipeline

October 14, 2003 Research and Development blockbusters, drug development, pipelines

Feature

The European private pharma sector

October 14, 2003 Research and Development pharma, private

Feature

The biotech sector’s growth-innovation paradox

October 9, 2003 Research and Development biotech, innovation

The biotech sector is facing a paradox. Traditionally, the strength of the sector has been based on the ability of …
Feature

The pharmaceutical doll’s house

October 9, 2003 Research and Development biotech

The turn of the century has witnessed a period of intense uncertainty and instability within the pharma sector. After decades …
Feature

EDC: electronic data capture or eliminating data corruption?

October 8, 2003 Research and Development clinical trials, electronic data capture

Managing a successful clinical trial is probably one of the hardest tasks known to man. Getting a drug to work …
Feature

Collaboration across the pharma industry

October 8, 2003 Research and Development collaborations

Feature

Effective relief?

October 3, 2003 Research and Development sme, tax relief

Feature
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026